The Biotech Survival Charade: Stop Buying the "AI Pivot" HypeGlobal Report·1 day ago, 04:14 AMINM-4.09%ONCY-1.49%
Inside the Biotech Sector's Recent Clinical Catalyst WaveGlobal Report·2 days ago, 04:17 AMGENB+2.09%IBRX-1.55%
Consumer Resilience Meets Sector Divergence: A Microcosm for Fed OfficialsGlobal Report·2 days ago, 04:13 AMKR+1.95%TDC+4.45%
Oncolytics Biotech Disclosed Failure to Satisfy a Continued Listing Rule or StandardTradingView·Jul 24 at 03:43 PMONCY-1.49%
The AI Pivot Pain: Inside monday.com's Layoffs and the Broader Strategic OverhaulsGlobal Report·Jul 24 at 04:13 AMMNDY+6.03%NTNX+3.29%
Columbia Financial's USD 1.7B Raise and Timken's Guidance Hike Lead Mid-2026 Strategic ShiftsGlobal Report·Jul 22 at 04:18 AMCLBK-0.28%TKR-0.14%
Oncolytics Biotech wins FDA Fast Track status for pelareorep in second-line anal cancerPUBT·Jul 20 at 08:08 AMONCY-1.49%
The Divergence of Moats: Physical Infrastructure, Strategic Pivots, and Survival MechanicsGlobal Report·Jul 19 at 04:12 AMWU-0.61%NAK-3.16%
